Clinical Trial Update: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of nivolumab and relatlimab in metastatic uveal melanoma has completed, with results posted in February 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: Jose Lutzky, MD | Conditions: Metastatic Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-02-13